Together, these findings highlight gain-of-function mutations in NSD family genes as critical epigenetic drivers of tumorigenesis, positioning NSD2 and NSD3 as promising biomarkers and therapeutic targets for cancer treatment. This evidence concerns the gene SLC17A5 and cancer.